MP52-12 COMPARISON OF ALTERNATIVE ANDROGEN RECEPTOR-AXIS-TARGETED AGENT (ARATA) VERSUS DOCETAXEL AS SECOND-LINE THERAPY FOR PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PROGRESSING AFTER INITIAL ARATA IN REAL-WORLD CLINICAL PRACTICE IN JAPAN
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.